Lilly’s Prasugrel Could Gain FDA Approval In June
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-clotting agent was granted a six-month priority review by FDA.
You may also be interested in...
Prasugrel: To Be (Approved) Or Not To Be
FDA will soon weigh in; the action date for Lilly/Daiichi’s Plavix competitor is June 26.
Prasugrel: To Be (Approved) Or Not To Be
FDA will soon weigh in; the action date for Lilly/Daiichi’s Plavix competitor is June 26.
Triple Dose Of Good News At Heart Meeting
Pioglitazone, prasugrel and telmisartan prove strong in studies’ data.